In connection with pretreated HR-positive, HER2-negative breast cancer, the TROPION-Breast01 trial studied datopotamabderuxtecan with a PFS of 6.9 months, compared to 4.9 months estimated for standard chemotherapy (HR = 0.63; p < 0.001). This evidence concerns the gene ERBB2 and breast carcinoma.